Redeye provides an initial take following the release of Optomed’s Q3 2026 report. Sales came in below our expectations, and although growth was high, the quarter was boosted by the large cEUR1.9m device order. On the positive side, cost control was strong, and Optomed reported positive EBITDA, EBIT and operating cash flow. Overall, we had hoped for a better sales development, but the cost control partly makes up for it. We will publish a research update shortly, in which we expect to make some downward adjustments to our short-term sales estimates and some positive adjustments to our OPEX estimates.
LÄS MER
